Provided herein are methods of treating ANCA-associated vasculitis (AAV) in individuals in need thereof comprising administering a complement component 5a receptor (C5aR) antagonist. Also provided herein are methods of treating a ANCA-associated vasculitis (AAV) with renal involvement in an individual in need thereof comprising administering a complement component 5a receptor (C5aR) antagonist to the individual if the individual exhibits an elevated urinary soluble CD163 (sCD163) to creatinine ratio compared to individuals without AAV. In some embodiments, the complement component 5a receptor (C5aR) antagonist is avacopan.

Among the various aspects of the present disclosure is the provision of a method of detection, treatment, and monitoring of cardiovascular disease or a foot wound by detection of a novel biomarker, Fatty Acid Synthase (FAS).

A method is described for the diagnosis of rosacea. The method can include a step of measuring the expression of at least one peptide from the galanin family in a sample of biological fluid from a patient. Also described, is a related diagnostic kit.

Inflammatory cell recruitment to local sites of tissue injury and/or infection is controlled by many signaling processes influencing cell-to-cell interactions between vascular endothelial cells (EC) in post-capillary venules and circulating leukocytes. Here we report that the ATP-release channel Pannexin1 (Panx1) opens downstream of EC activation by tumor necrosis factor (TNF ). This process involves activation of Type 1 TNF receptors, recruitment of Src Family Kinases (SFK), and SFK-dependent phosphorylation of Panx1. We report a previously unidentified role for Panx1 channels in promoting leukocyte adhesion and emigration through the venous wall during acute systemic inflammation. The present application further discloses that Panx IL2 peptide consisting of amino acid sequence KYPIVEQYLKYGRKKQRR (SEQ ID NO: 3) or .sup.10Panx1 peptide consisting of amino acid sequence WRQAAFVDSY (SEQ ID NO: 8) are inhibitors of leukocyte adhesion.

A method of diagnosing Kawasaki disease in a mammal is provided. The method comprises determining in a biological sample obtained from the mammal the expression level of at least IL-1RA, and optionally the level of one or more of, IL-I, IL-18 and IL-18 BP, and diagnosing Kawasaki disease when the levels of these biomarkers is elevated in comparasion to febrile control levels.

Provided herein are methods for diagnosing the presence or the risk of development, or for the therapy control of vasculitis, in particular of large vessel vasculitis, like giant-cell arteritis (GCA), polymyalgia rheumatica (PMR), and Takayasu's arteritis, in a subject analyzing for the presence of antibodies against ferritin, in particular heavy chain ferritin or immunoreactive peptides thereof or ferritin analog protein, preferably bacterial ferritin analog protein, or immunoreactive peptides thereof, in a subject. In addition, test kits for use in the diagnosis of the presence or the risk of development, or for the therapy control of vasculitis, in particular of large vessel vasculitis, like GCA, PMR and Takayasu's arteritis, in a subject are also provided.

Means and methods for determining whether an individual that does not have rheumatoid arthritis, AAV or Sjgren syndrome at the moment of sampling is at risk of developing the disease, the method comprising determining whether an antibody-containing sample of the individual comprises an autoantibody associated with the disease that comprises an N-linked glycosylation at one or more positions in a Fab-portion of the antibody, the method further comprising determining the risk of the individual for developing the disease. The disease is preferably rheumatoid arthritis.

The present invention provides for compositions and methods for diagnosing and treating Kawasaki disease. More specifically, the proteomes of patients with KD are enriched for the meprin A, filamin B, and filamin C, which serve as biomarkers (and potential therapeutic targets) for KD. Accordingly, detection of these biomarkers, using compositions and methods provided for herein, can inform the therapy delivered to the subject.

Described is a method of diagnosing, treating, or monitoring a treatment for Kawasaki disease in a subject. The method includes detecting the level of a biomarker in a sample obtained from the subject, the biomarker being IL-7F, sCD40L, MPIF-1, E-selectin, IP-10, or IL-33. The level is compared to a cut-off level. Also described is a kit for carrying out the method.

Means and methods for determining whether an individual that does not have rheumatoid arthritis, AAV or Sjgren syndrome at the moment of sampling is at risk of developing the disease, the method comprising determining whether an antibody-containing sample of the individual comprises an autoantibody associated with the disease that comprises an N-linked glycosylation at one or more positions in a Fab-portion of the antibody, the method further comprising determining the risk of the individual for developing the disease. The disease is preferably rheumatoid arthritis.